Kaken Pharmaceutical Management
Management criteria checks 2/4
Kaken Pharmaceutical's CEO is Hiroyuki Horiuchi, appointed in Jun 2020, has a tenure of 5.25 years. total yearly compensation is ¥123.00M, comprised of 56.1% salary and 43.9% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth ¥29.73M. The average tenure of the management team and the board of directors is 5.3 years and 2.8 years respectively.
Key information
Hiroyuki Horiuchi
Chief executive officer
JP¥123.0m
Total compensation
| CEO salary percentage | 56.10% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 5.3yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
We Think Kaken Pharmaceutical's (TSE:4521) Robust Earnings Are Conservative
May 19
We Think Kaken Pharmaceutical (TSE:4521) Can Manage Its Debt With Ease
May 12There's Reason For Concern Over Kaken Pharmaceutical Co., Ltd.'s (TSE:4521) Price
Apr 15Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00
Mar 27Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00
Mar 13Kaken Pharmaceutical (TSE:4521) Has Affirmed Its Dividend Of ¥75.00
Feb 27Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00
Feb 10Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00
Jan 10Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00
Dec 20Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00
Dec 02Estimating The Intrinsic Value Of Kaken Pharmaceutical Co., Ltd. (TSE:4521)
Aug 13Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00
Jul 26Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00
Jul 11Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00
Mar 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | JP¥12b |
| Mar 31 2025 | JP¥123m | JP¥69m | JP¥14b |
Compensation vs Market: Hiroyuki's total compensation ($USD820.66K) is about average for companies of similar size in the JP market ($USD1.00M).
Compensation vs Earnings: Insufficient data to compare Hiroyuki's compensation with company performance.
CEO
Hiroyuki Horiuchi (63 yo)
Mr. Hiroyuki Horiuchi serves as Director of Kaken Pharmaceutical Co. Ltd. since June 2016 and has been its President since June 2020. He is the Chairman of Kaken Pharmaceutical Co. Ltd.He was Chief Office...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 5.3yrs | JP¥123.00m | 0.020% ¥ 29.7m | |
| General Manager of Legal Affairs & Intellectual Property Department | less than a year | no data | no data | |
| Chief Officer of Marketing & Sales Division | no data | no data | no data | |
| MD & Director | 5.4yrs | no data | 0.0084% ¥ 12.4m | |
| Head of Research and Development & Director | no data | no data | 0.0063% ¥ 9.3m | |
| Director of Pharmaceutical Affairs Division & Executive officer | no data | no data | no data | |
| Deputy Chief Officer of R&D Division & Chief of Drug Research Center | no data | no data | no data | |
| Chief Officer of Production Division & Chief of Shizuoka Factory | no data | no data | no data |
Experienced Management: 4521's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.3yrs | JP¥123.00m | 0.020% ¥ 29.7m | |
| MD & Director | 4.3yrs | no data | 0.0084% ¥ 12.4m | |
| Head of Research and Development & Director | 2.3yrs | no data | 0.0063% ¥ 9.3m | |
| Independent Outside Director | 5.3yrs | no data | 0.0013% ¥ 1.9m | |
| Independent Outside Director | 4.3yrs | no data | 0.00026% ¥ 380.0k | |
| Outside Audit & Supervisory Board Member | 2.3yrs | no data | 0.00026% ¥ 380.0k | |
| Auditor | 2.3yrs | no data | 0.015% ¥ 22.4m | |
| Director | 1.3yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | 4.3yrs | no data | 0.0011% ¥ 1.5m | |
| Standing Audit & Supervisory Board Member | 3.3yrs | no data | 0.0050% ¥ 7.3m | |
| Independent Outside Director | 1.3yrs | no data | no data | |
| Director | less than a year | no data | no data |
Experienced Board: 4521's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/26 13:24 |
| End of Day Share Price | 2025/09/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kaken Pharmaceutical Co., Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |
| Junya Yamazaki | Jefferies LLC |
| Toshiyuki Iwata | Mizuho Securities Co., Ltd. |